Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. 2001

K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
Teikyo University Institute of Medical Mycology, 359 Otsuka, Hachioji, Tokyo 192-0395, Japan. Kazunori_Maebashi@meiji.co.jp

Four Candida albicans isolates, TIMM 3163, TIMM 3164, TIMM 3165 and TIMM 3166, with reduced fluconazole susceptibility were obtained from three AIDS patients in Japan, and the mechanisms of their drug resistance were studied. All isolates showed lower levels of intracellular accumulation of fluconazole than ATCC 10231, a susceptible control strain of C. albicans. Increased amounts of CDR1 and CDR2 mRNA encoding putative ATP binding cassette (ABC) transporters were associated with the azole resistance of all TIMM isolates, apart from TIMM 3164. In addition, increased Cdr1p levels were immunodetected in the cell membrane fractions of all the TIMM strains except for TIMM 3164. Gene amplification was not responsible for CDR1 overexpression and there were no significant differences in the mRNA levels of CDR3 or CDR4 (ABC transporters) in the azole-susceptible and -resistant cells. CaMDR1 (a major facilitator superfamily) gene expression was not observed in any of the resistant isolates or the control strain. These results suggest that energy-dependent drug efflux associated with increased expression of CDR1 and CDR2 is involved in the fluconazole resistance mechanisms in two of the four isolates, TIMM 3165 and TIMM 3166. TIMM 3164 demonstrated energy-dependent drug efflux without overexpression of CDR1-4 or CaMDR1, indicating that some other pump may be operating. Despite showing low levels of drug efflux and overexpression of CDR1 and CDR2, efflux in TIMM 3163 was not energy dependent, suggesting that the expressed Cdr1p non-functional Cdr1p and that other resistance mechanisms may operate in this strain.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D002569 Cerulenin An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function. 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005656 Fungal Proteins Proteins found in any species of fungus. Fungal Gene Products,Fungal Gene Proteins,Fungal Peptides,Gene Products, Fungal,Yeast Proteins,Gene Proteins, Fungal,Peptides, Fungal,Proteins, Fungal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
May 2006, International journal of antimicrobial agents,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
November 1996, Lancet (London, England),
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
February 2016, Mycoses,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
September 2004, Diagnostic microbiology and infectious disease,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
March 2016, Journal de mycologie medicale,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
January 2004, European review for medical and pharmacological sciences,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
March 1995, Journal of clinical microbiology,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
June 2002, Antimicrobial agents and chemotherapy,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
November 1995, Antimicrobial agents and chemotherapy,
K Maebashi, and M Niimi, and M Kudoh, and F J Fischer, and K Makimura, and K Niimi, and R J Piper, and K Uchida, and M Arisawa, and R D Cannon, and H Yamaguchi
November 1993, Journal of clinical microbiology,
Copied contents to your clipboard!